JJDC

To add a bio or update investment portfolio, please click update information.

Investment Portfolio

Mestag Therapeutics secures £30m to advance fibroblast immunology cancer therapies

16 Mar 2026

Mestag Therapeutics secures £30m to advance fibroblast immunology cancer therapies

Mestag Therapeutics develops antibody treatments based on fibroblast immunology for cancer and inflammatory diseases. It is building therapies designed to direct and drive immune responses using fibroblast-immune biology.

JJDC

- Life Sciences
1(12 months)
jnjinnovation.com/home
Update Information

More venture news

OpenTrade
6 May 2026
OpenTrade raises £12.5m in funding led by Mercury Fund and Notion Capital to power stablecoin yield products for neobanks and crypto platforms
EquityCrypto
SugaROx
5 May 2026
SugaROx lands £2.5m in funding from The Mosaic Company to develop crop biostimulants that improve yield and quality
EquityAgriculture
NunaBio
5 May 2026
NunaBio raises £6.5m led by Northstar Ventures to manufacture high fidelity synthetic DNA at scale
EquityLife Sciences

JJDC

Investment Portfolio

Mestag Therapeutics secures £30m to advance fibroblast immunology cancer therapies

More venture news

OpenTrade raises £12.5m in funding led by Mercury Fund and Notion Capital to power stablecoin yield products for neobanks and crypto platforms

SugaROx lands £2.5m in funding from The Mosaic Company to develop crop biostimulants that improve yield and quality

NunaBio raises £6.5m led by Northstar Ventures to manufacture high fidelity synthetic DNA at scale